GlassScriptPhysician profile
Rajeev Chauhan
NPI 1104812437
$32,407.20
in general payments reported to CMS, 2019-2025
34 companies · $2,343 in 2025
The $2,343 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $2,870 · 2021: $927 · 2022: $3,311 · 2023: $5,095 · 2024: $1,173 · 2025: $2,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,967 · Food and Beverage: $3,679 · Travel and Lodging: $690 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,967.00 |
| Food and Beverage | $3,679.00 |
| Travel and Lodging | $689.52 |
| Education | $276.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $12,947.86 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $7,414.31 | 2019-2024 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $6,452.79 | 2019-2025 | Jynarque |
| Vantive US Healthcare LLC | $962.12 | 2025 | Renal - Chronic |
| Opko Pharmaceuticals, LLC | $613.64 | 2019-2025 | Rayaldee |
| Amgen INC. | $538.11 | 2022-2025 | Krystexxa, Parsabiv, Aranesp |
| Mallinckrodt Hospital Products INC. | $510.65 | 2021-2025 | Acthar |
| Baxter Healthcare | $367.75 | 2019-2024 | Renal - Pd, Suprane, Renal - Acute |
| Bayer Healthcare Pharmaceuticals INC. | $342.47 | 2022-2025 | |
| Novo Nordisk INC | $233.74 | 2024-2025 | Ozempic, Rybelsus |
| Akebia Therapeutics INC | $206.03 | 2020-2025 | Vafseo, Auryxia |
| Glaxosmithkline, LLC. | $200.30 | 2019-2024 | Benlysta |
| Horizon Therapeutics Plc | $195.50 | 2020-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $186.32 | 2023-2025 | |
| Inari Medical, INC. | $161.12 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $142.58 | 2020-2024 | Ultomiris |
| Travere Therapeutics, INC. | $139.55 | 2020-2025 | Filspari |
| Ardelyx, INC. | $136.77 | 2024-2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $104.16 | 2019 | |
| Alnylam Pharmaceuticals INC. | $82.55 | 2021-2024 | Oxlumo |
| Kyowa Kirin, INC. | $77.61 | 2024 | Crysvita |
| Calliditas Therapeutics US INC. | $70.56 | 2024-2025 | Tarpeyo |
| Cormedix INC. | $63.60 | 2024 | Defencath |
| Fresenius USA Marketing, INC. | $55.91 | 2022-2024 | Velphoro |
| Daiichi Sankyo INC. | $45.61 | 2023-2024 | Injectafer |
| Aurinia Pharma U.S., INC. | $42.62 | 2022-2023 | Lupkynis |
| Scpharmaceuticals INC. | $24.50 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.81 | 2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $23.12 | 2019 | |
| Fresenius USA Manufacturing, INC. | $21.99 | 2025 | |
| Apellis Pharmaceuticals, INC. | $19.55 | 2025 | Empaveli |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Chauhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.